Asarfi Hospital Q1 FY27 Results (BSE: 543943)
Signal: Growth reaccelerated
The read
The key trajectory is sustained hospital operating momentum: consolidated revenue rose 33.2% YoY to ₹4,753.41 lakh, OPD revenue increased 44% YoY, and PAT grew 36.7% to ₹426.72 lakh as higher ARPOB and case mix supported about 20% EBITDA margin; growth remains strong, though it is moderating from the 55.7% revenue growth recorded in Q1FY26.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹47.53 Cr | +33.2% | N/A |
| Net profit | ₹4.27 Cr | +36.7% | |
| EPS | ₹2.17 | +36.5% | |
| EBIT margin | 20% |
P&L walk
Consolidated revenue increased to ₹4,753.41 lakh, +33.2% YoY, and EBITDA margin was about 20%; PAT grew faster at +36.7% to ₹426.72 lakh despite other income falling 60.0%, indicating operating growth rather than treasury income drove earnings.
Segments
There is no reported segment table; standalone PAT of ₹426.84 lakh versus consolidated PAT of ₹426.72 lakh indicates no material subsidiary drag or uplift.
Key positives
- Consolidated revenue reached ₹4,753.41 lakh, up 33.2% YoY, with growth supported by higher patient volumes and realizations rather than other income.
- OPD revenue grew 44% YoY, while ARPOB increased to ₹23,498 in the super-specialty unit and ₹31,892 in the cancer unit, supporting revenue mix and realization quality.
- PAT rose 36.7% to ₹426.72 lakh despite other income declining 60.0% to ₹56.59 lakh, indicating that earnings growth was primarily operating-led.
- EBITDA margin was about 20%, described by management as an expansion driven by improved ARPOB, realizations and case mix.
Key concerns
- Revenue growth of 33.2% YoY is lower than the 55.7% YoY growth recorded in Q1FY26, indicating some moderation even though the absolute revenue base reached ₹4,753.41 lakh.
Research and educational content only. Not investment advice.